Julie Mercier, BS

Team Manager (BPI)
Altasciences
Montreal, QC, Canada

Disclosure: Acurx Pharmaceuticals, LLC: Research Grant or Support

Presentation(s):

• LB7 - A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase IIIC (polIIIC) Inhibitor

  Thursday, October 3
  2:45 PM – 2:55 PM